Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $350.64 | 20 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $160.78 | 10 | $0 (2021) |
| BTG INTERNATIONAL, INC. | $64.00 | 2 | $0 (2020) |
| Genentech USA, Inc. | $44.17 | 3 | $0 (2021) |
| Allergan, Inc. | $30.77 | 2 | $0 (2020) |
| Becton, Dickinson and Company | $21.16 | 1 | $0 (2021) |
| GlaxoSmithKline, LLC. | $17.01 | 1 | $0 (2020) |
| PFIZER INC. | $12.75 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $74.04 | 4 | Janssen Pharmaceuticals, Inc ($39.82) |
| 2020 | $172.36 | 9 | BTG INTERNATIONAL, INC. ($64.00) |
| 2019 | $47.94 | 3 | Allergan Inc. ($18.11) |
| 2018 | $32.68 | 2 | Janssen Pharmaceuticals, Inc ($32.68) |
| 2017 | $23.62 | 2 | PFIZER INC. ($12.75) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: Virology & Specialty Care | ||||||
| 10/01/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/14/2021 | Becton, Dickinson and Company | — | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: BD Interventional Access Systems | ||||||
| 04/22/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/30/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/03/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/17/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/26/2020 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: VACCINES | ||||||
| 05/07/2020 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $12.66 | General |
| 05/06/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/18/2020 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Virology & Specialty Care | ||||||
| 02/06/2020 | BTG INTERNATIONAL, INC. | CROFAB (Drug) | Food and Beverage | Cash or cash equivalent | $34.00 | General |
| Category: ANTI-VENOM | ||||||
| 02/06/2020 | BTG INTERNATIONAL, INC. | CROFAB (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: ANTI-VENOM | ||||||
| 09/13/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/30/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/31/2019 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Virology & Specialty Care | ||||||
| 09/05/2018 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/08/2018 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/10/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/16/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,715 | 5,954 | $313,245 | $145,700 |
| 2022 | 13 | 790 | 1,330 | $88,228 | $49,095 |
| 2021 | 13 | 892 | 1,268 | $108,132 | $64,418 |
| 2020 | 15 | 1,059 | 1,852 | $119,469 | $64,251 |
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 418 | 574 | $100,000 | $53,376 | 53.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 375 | 375 | $93,200 | $43,867 | 47.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 351 | 397 | $39,700 | $13,441 | 33.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 269 | 584 | $11,680 | $9,212 | 78.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 121 | $18,150 | $7,659 | 42.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 84 | 84 | $14,925 | $6,198 | 41.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 251 | 435 | $15,225 | $4,123 | 27.1% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 181 | 190 | $3,805 | $2,981 | 78.3% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 19 | 20 | $1,600 | $1,006 | 62.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 40 | 40 | $2,400 | $891.73 | 37.2% |
| 81002 | Urinalysis, manual test | Office | 2023 | 118 | 143 | $1,430 | $487.63 | 34.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 138 | 604 | $3,020 | $442.07 | 14.6% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 11 | 12 | $1,215 | $423.95 | 34.9% |
| 87807 | Detection test by immunoassay with direct visual observation for respiratory syncytial virus | Office | 2023 | 30 | 30 | $600.00 | $369.79 | 61.6% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 13 | 14 | $780.00 | $287.51 | 36.9% |
| 90471 | Administration of vaccine | Office | 2023 | 21 | 21 | $735.00 | $283.08 | 38.5% |
| 90714 | Diphtheria and tetanus vaccine (7 years or older) | Office | 2023 | 12 | 12 | $660.00 | $233.81 | 35.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 188 | 2,070 | $2,070 | $172.87 | 8.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 14 | 14 | $700.00 | $134.70 | 19.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 40 | 158 | $790.00 | $55.45 | 7.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 12 | 12 | $120.00 | $38.52 | 32.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 19 | 44 | $440.00 | $17.09 | 3.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 95 | 95 | $23,100 | $13,693 | 59.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 101 | 108 | $18,575 | $11,341 | 61.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 75 | 79 | $11,775 | $6,019 | 51.1% |
About Dr. Minh Nguyen, DO
Dr. Minh Nguyen, DO is a Emergency Medicine healthcare provider based in Midlothian, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1184882573.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Minh Nguyen, DO has received a total of $350.64 in payments from pharmaceutical and medical device companies, with $74.04 received in 2021. These payments were reported across 20 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($350.64).
As a Medicare-enrolled provider, Nguyen has provided services to 5,456 Medicare beneficiaries, totaling 10,404 services with total Medicare billing of $323,465. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Practice Information
- Specialty Emergency Medicine
- Location Midlothian, TX
- Active Since 06/02/2008
- Last Updated 12/27/2024
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1184882573
Products in Payments
- XARELTO (Drug) $128.10
- CROFAB (Drug) $64.00
- Xofluza (Drug) $44.17
- INVOKANA (Drug) $32.68
- DALVANCE (Drug) $18.11
- BEXSERO (Biological) $17.01
- ELIQUIS (Drug) $12.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Midlothian
Raymond Decker, Md, MD
Emergency Medicine — Payments: $22,109
William Watterson, M.d, M.D
Emergency Medicine — Payments: $10,102
Frank Ramsey, M.d, M.D
Emergency Medicine — Payments: $162.82
Uduak Akan-Etuk, M.d, M.D
Emergency Medicine — Payments: $135.02
Dr. Christopher Hughes, Do, DO
Emergency Medicine — Payments: $128.64
Christian Jenski, M.d, M.D
Emergency Medicine — Payments: $112.63